By IDSE News Staff
The first clinical trial of a three-month tuberculosis treatment regimen is closing enrollment because many people in the treatment group experienced ongoing or recurring TB.
The AIDS Clinical Trials Group 5362, also known as the CLO-FAST trial, sought to evaluate the safety and efficacy of a three-month clofazimine- and high-dose rifapentine-containing regimen (ClinicalTrials.gov Identifier: NCT04311502). An interim data analysis showed that participants taking the